MD Anderson Cancer Center, Oncora Medical Team Up To Fight Cancer With Precision Medicine Alliance

PHILADELPHIA and HOUSTON, April 4, 2017 /PRNewswire/ -- Oncora Medical, a precision radiation oncology software company, and The University of Texas MD Anderson Cancer Center, today announced a strategic alliance focusing on building the next generation of precision medicine software for radiation oncology.

During Phase I, MD Anderson oncologists and information technology professionals will work with Oncora’s team of data scientists and engineers to install Oncora’s Precision Radiation Oncology Platform, a software system built to assist radiation oncologists in the development of personalized treatment plans based on outcome predictions. Oncora’s platform will be fueled by data from MD Anderson’s electronic medical record system, tumor registry, radiation therapy planning system, and Brocade, an innovative software product developed by MD Anderson in 2014. Brocade was developed by Benjamin Smith, M.D., associate professor of Radiation Oncology, and author of a study published in the April 2016 issue of the Journal of the American College of Radiology that demonstrated a 70 percent reduction in the time physicians spend documenting clinical data using Brocade.

Brocade, a web-based clinical documentation tool used by MD Anderson radiation oncologists, enables intuitive collection of structured data about patient diagnosis, treatment and radiation side effects, and generates narrative-style clinical documentation for medical records.

Oncora will engineer complete interoperability between their Precision Radiation Oncology Platform and Brocade to explore the potential value of a combined product.

“This partnership provides an opportunity for precision medicine to truly improve the way cancer treatments are designed and delivered,” said Oncora Medical co-founder and CEO, David Lindsay. “We’re excited to work with MD Anderson in an effort to improve care for patients.”

Precision medicine delivering the best treatment to the right patient at the optimal time could improve cancer survival rates while minimizing unintended side effects. Tools for collecting quality clinical data and predicting specific radiation treatment outcomes are necessary to make precision medicine a reality.

“We believe this partnership could be a significant step forward for the field of radiation oncology and our patients,” said Smith. “Through this alliance, we hope to improve workflows and processes for radiation oncologists and simultaneously give radiation oncologists access to better information to support real-time, precision medical decision making.”

About Oncora Medical:
Oncora Medical, Inc., a software startup in Philadelphia, PA, has developed a powerful predictive analytics platform for oncology, capable of analyzing diverse healthcare data and applying advanced machine learning techniques to produce valuable clinical insights. Currently, Oncora is working to improve the radiation therapy experience (both for physicians and their patients) with software to help oncologists design more personalized radiation treatment plans.

About MD Anderson:
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 47 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals since the survey began in 1990, and has ranked first for nine of the past 10 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/md-anderson-oncora-medical-team-up-to-fight-cancer-with-precision-medicine-alliance-300433344.html

SOURCE Oncora Medical

MORE ON THIS TOPIC